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Abstract
Exocrine pancreatic insufficiency (EPI) is a common problem after surgery of the pancreas and stomach.
It is usually caused by inadequate pancreatic enzyme activity resulting from insufficient enzyme produc-
tion, insufficient enzyme activation or disturbed enzyme deactivation. A variety of direct and indirect
pancreatic function tests such as the secretin–cerulein test, the faecal elastase test and the 13C-mixed
triglyceride breath test are used to assess exocrine pancreatic function. Few studies have addressed
pancreatic enzyme replacement therapy (PERT) following pancreatic surgery. These studies suggest
beneficial effects of enzyme replacement after pancreatic resections. A number of studies have been
performed to assess post-gastrectomy maldigestion and PERT. The treatment options remain controver-
sial, although the published evidence is in favour of PERT leading to an overall improvement of symptoms.
In conclusion, EPI following pancreatic surgery and total or partial gastrectomy remains a common clinical
challenge. As a result of the lack of solid evidence, more clinical trials, particularly randomized, controlled
clinical trials, are urgently needed.
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Introduction
Exocrine pancreatic insufficiency (EPI) is a common clinical
problem after pancreatic or gastric surgery.1 It is defined as inad-
equate pancreatic enzyme activity for digestion, caused by insuf-
ficient enzyme production, insufficient enzyme activation or
disturbed enzyme deactivation.2 Other than post-surgery patients,
EPI mostly affects infants and children suffering from cystic fibro-
sis, Shwachman–Diamond syndrome or pancreatic agenesis. In
adults, the aetiology is diverse, with the underlying diseases being
acute or chronic pancreatitis, pancreatic neoplasms, pancreatic
resections (partial or total pancreatectomy), short bowel syn-
dromes, hereditary haemochromatosis and partial or total gas-
trectomy. Importantly, elderly patients newly diagnosed with
symptoms of EPI should undergo an immediate check-up for
pancreatic cancer, particularly if co-morbid diabetes mellitus has
also been newly diagnosed.3 The symptoms of EPI are maldiges-
tion or malabsorption and, specifically, malnutrition with weight
loss, steatorrhoea, vitamin deficiencies (especially of vitamins A,
D, E, K) and, of course, diabetes mellitus, which in turn may also
be a cause of EPI.
Pancreatic function tests
The diagnosis of EPI is made by either direct or indirect pancre-
atic function tests (Table 1).4,5 The cholecystokinin (CCK) test, the
secretin test, the secretin–CCK test, the endoscopic pancreatic
function test and the Lundh test are direct tests potentially avail-
able in clinical practice.6 In the CCK test, the patient receives CCK
or an analogue, and enzymes are collected using a duodenal tube
during an 18-min test period.7 The disadvantage of this test is that
the determination of perfusion markers requires a specialized
laboratory. The secretin test also makes use of a double-lumen
gastroduodenal tube with which samples are collected at 15-min
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intervals during a 1-h period after secretin simulation.4,8 This test
is relatively easy to perform and constitutes one of the most fre-
quently used tests in the clinical setting. In addition, the secretin–
CCK test can be performed; however, the secretin-induced rapid
water flow may result in diluted and unreliable enzyme collec-
tions. In addition to these classical tests, the endoscopic pancreatic
function test is sometimes used, with endoscopic aspirations at 0,
15, 30, 45 and 60 min. This test has recently attracted considerable
clinical attention because it is preferred by many patients for the
greater comfort with which it can be performed compared with
other tests, and the availability of standardized endoscopy.9 The
Lundh test, in which a duodenal tube is necessary, is usually con-
founded in patients with small bowel mucosal diseases and is
more complicated to carry out because it requires a liquid test
meal as a stimulus.10–12 However, these direct pancreatic function
tests are less comfortable for the patient and therefore indirect
pancreatic function tests are considered to be more acceptable to
patients and their doctors.
The faecal elastase-1 test remains one of the most frequently
used indirect tests in the clinical setting, although it has a poor
sensitivity for early pancreatic insufficiency.13,14 However, it is
highly sensitive and specific for advanced EPI and is easily per-
formed. The 24-h and 72-h stool fat tests are often affected by
inadequate patient compliance and are therefore rarely used.
In addition, there are novel indirect tests that have not yet been
extensively studied, such as the secretin-enhanced magnetic reso-
nance imaging test. The classical serum or urine pancreolauryl
tests, whichmeasure intraluminal pancreatic enzyme function, are
limited in patients with bile salt deficiency, coeliac disease, renal
failure and post-gastrectomy symptoms, and are therefore also
being abandoned in the clinical setting.15 Most recently, the 13C-
mixed triglyceride breath test has attracted considerable clinical
attention and is being evaluated in clinical studies. Its results
are promising; the test is simple and its findings are reliable.16–19
Treatment options
The therapeutic options for the treatment of EPI involve, firstly,
nutritional changes, which include a high-carbohydrate diet, a
normal fat diet and, optionally, medium-chain triglycerides, con-
sumed in several (five to seven) small meals.20 These changes are
easily implemented and can be recommended for most patients
suffering from EPI following surgery of the pancreas or stomach.
In addition, pancreatic enzyme replacement therapy (PERT)
may be provided orally; the dose can be adapted to meals and
should not fall below 25 000–50 000 units (U) of lipase/meal.
As lipase is irreversibly deactivated by gastric acid, patients receiv-
ing uncoated enzyme preparations may require simultaneously
administered proton pump inhibitors (PPIs).21 Omitting PPIs is
common because many patients are not aware of the importance
of these drugs in conjunction with uncoated enzyme formula-
tions. Enteric-coated enzyme preparations are resistant to gastric
acid and in the majority of patients do not require concomitant
PPI administration; however, in patients with EPI who have an
incomplete response to PERT, the addition of a PPI may signifi-
cantly improve and even normalize fat digestion.21 To prevent low
vitamin levels, especially in patients with severe diarrhoea, lipo-
soluble vitamins (A, D, E, K) must be parenterally substituted.
Clinical considerations
Acute pancreatitis
Following acute pancreatitis, the incidence of EPI mostly depends
on the severity of the attack, but it occurs in up to 86% of patients
who have suffered from severe acute necrotizing pancreatitis.22,23
Furthermore, the severity of the disease is not only associated with
EPI, but, of course, also with endocrine pancreatic insufficiency.
Post-pancreatectomy EPI
Exocrine pancreatic insufficiency is common following pancrea-
tic resections, including classical or pylorus-preserving Whipple
Table 1 Summary of direct and indirect pancreatic function tests
Tests Disadvantages
Direct tests
CCK Requires specialized laboratory
Secretin 1-h collection
Secretin–CCK Potential for diluted, unreliable enzyme collections
Endoscopic pancreatic function None
Lundh Confounded in small bowel mucosal diseases
Indirect tests
Faecal elastase-1 Poor sensitivity for early EPI
24-h and 72-h stool fat Often inadequate patient compliance
Secretin-enhanced MRI Limited assessment
Serum/urine pancreolauryl Limited in bile salt deficiency, coeliac disease, renal failure and post-gastrectomy
13C-mixed triglyceride Currently under evaluation
CCK, cholecystokinin; EPI, exocrine pancreatic insufficiency; MRI, magnetic resonance imaging
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operations, duodenum-preserving pancreatic head resections,
left pancreatic resections and resections for benign tumours.24,25
PERT has been tested in only two randomized clinical trials. In
one study, the absorption coefficient for fat was significantly worse
in the placebo group, as was the absorption coefficient for energy
(Fig. 1).26 In a study by Neoptolemos et al., 39 patients were ran-
domized to standard- or high-dose pancreatin following pancre-
atic resection.27 Although stool fat excretion and stool volume
(P < 0.0001) and stool frequency (P < 0.01) correlated with the
pancreatin dose, there were no associations between PERT and
abdominal pain and global symptoms. Therefore, current evi-
dence does not generally recommend the use of PERT after pan-
creatic surgery. However, clinical experience favours enzyme
supplementation, including 100 000 U pancreatin (CREON®;
Solvay Pharmaceuticals GmbH, Hannover, Germany) taken
together with meals. If these treatment options are not successful,
further diagnostic measures should be taken.
As there is no randomized, controlled trial evidence regarding
PERT following pancreatic resections, randomized clinical studies
are urgently required.
Post-gastrectomy EPI
Following gastric resections, EPI is a common clinical problem
that may reflect a reduced enzyme-release response to endogenous
stimulation or to reduced enzyme activation caused by bacterial
overgrowth.25 In a study by Friess et al., 15 patients who had
undergone total gastrectomy with preservation of the duodenal
food passage were tested for pancreatic juice volume, trypsin,
chymotrypsin, amylase and bicarbonate secretion after stimula-
tion.28 All of these parameters were found to be reduced following
total gastrectomy compared with preoperative levels. Further-
more, these patients had pathological glucose tolerance, with
increased plasma insulin and glucagon levels. These findings
were associated with significantly lower gastrin and pancreatic
polypeptide secretion, although CCK plasma secretion was
increased. Armbrecht et al. conducted a double-blind, crossover
study of 15 patients who underwent surgery for gastric cancer
(gastric resection) and compared PERT with placebo.29 The
authors assessed abdominal symptoms, bowel habits, faecal fat
excretion and oro-caecal transit time. The median postoperative
follow-up was 20 months (range 4–156 months). The number of
stools did not differ between the placebo and treatment groups.
However, the stool score was significantly lower (better) and the
faecal fat excretion significantly reduced in the group of patients
who were treated with PERT. Therefore, the authors concluded
that PERT after gastric resection for cancer reduced steatorrhoea
and improved stool consistency, but had no influence on pain,
vomiting, nausea, bloating or dumping. In another study by
Brägelmann et al., 52 institutionalized patients with a faecal fat
output 14 g/day were randomized to receive either pancreatic
enzymes or placebo for 14 days.30 All of these patients had under-
gone total gastrectomy for gastric cancer and their postoperative
follow-up ranged between 39 and 869 days. The endpoints of
this study were abdominal symptoms, faecal frequency and faecal
consistency. Interestingly, an overall improvement in symptoms
was found in significantly more enzyme-treated patients than
placebo-treated subjects (P < 0.01). However, no differences were
found regarding body mass index, bowel habits or fat malassimi-
lation. The authors concluded that PERT after total gastrectomy
has a positive effect on overall symptoms.
Conclusions
Exocrine pancreatic insufficiency after partial or total gastrectomy
is a main cause of maldigestion and postoperative weight loss and
should be treated with adequate PERT. Although the studies con-
ducted so far have included low numbers of patients and have
been unable to draw firm conclusions, they seem to justify PERT
in those patients who suffer from the classical clinical symptoms
of EPI following gastrectomy. Adequate substitution with pan-
creatic enzymes prevents maldigestion, improves postoperative
nutritional status and may improve non-specific symptoms.
However, in patients who have undergone pancreatic resections or
who suffer from primary pancreatic disorders (such as acute or
chronic pancreatitis), the evidence is much less solid. Although
PERT seems justified from a clinical viewpoint, no large random-
ized, controlled clinical trials have yet been performed. Such trials
are urgently required to confirm the clinical assumption that
PERT is necessary in most patients following pancreatic resection.
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Figure 1 Outcomes after 4 weeks of treatment with pancreatic
enzyme replacement therapy (PERT) or placebo in patients who had
previously received 4 weeks of individualized PERT following
surgery for chronic pancreatitis. *P = 0.02 vs. placebo26
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